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2015;8:e003744.Evaluating Statin Versus
Statin Plus Ezetimibe
for Coronary Plaque
RegressionTsujita et al. (1) reported the results of the PRECISE-
IVUS (Plaque Regression With Cholesterol Absorption
Inhibitor or Synthesis Inhibitor Evaluated by
Intravascular Ultrasound) trial which found that,
compared with standard statin monotherapy, the
combination of statin plus ezetimibe showed greater
coronary plaque regression in a secondary prevention
setting, and suggested that the clinical event risk
reduction in the IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial) (2)
might have been derived from the suppression effect
of coronary atherosclerotic development by dual
lipid lowering therapy. However, after 12 months of
follow-up in the PRECISE-IVUS trial (1) there have
been no differences in clinical events between the
two groups. Of note, in the similar population
enrolled in the IMPROVE-IT (2), with a follow-up
of 7 years, it has been shown that the truly
signiﬁcant event reductions, which led to the tiny
absolute beneﬁt in composite endpoint, of lowering
low-density lipoprotein cholesterol (LDL-C) with
ezetimibe added to simvastatin was driven by both
coronary revascularization (an endpoint notoriously
subject to preference that falsely inﬂates beneﬁts) (3)
and non-fatal myocardial infarction. Furthermore,
it was not mentioned how many myocardial
infarctions were procedure-related (2).
Indeed, loss of blinding to treatment allocation
might have probably occurred in the IMPROVE-IT (2)because dual lipid-lowering therapy predictably
greatly lowers LDL-C, and physicians who managed
the patients knew the lipid variables (4). Loss of
blinding might bias decisions about revascularization
procedures and, in the ezetimibe plus statin group,
loss of blinding could further result in fewer
myocardial infarctions secondary to these procedures
(5). The outcome least subject to bias is obviously
all-cause mortality. In the IMPROVE-IT, the striking
absence of beneﬁt in reducing deaths from any cause,
accompanied by the failure to reduce deaths from
cardiovascular cause and from coronary heart disease
in a high risk population, is worrying.
As practicing physicians, we would hesitate to
prescribe an expensive therapy which may lead, at
best, to few mm3 reduction in atheroma volume
without meaningful reductions in clinical events.*Luca Mascitelli, MD
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cet;380:18145.REPLY: Evaluating Statin Versus Statin Plus
Ezetimibe for Coronary Plaque RegressionWe have read with great interest the letter by Drs.
Mascitelli and Goldstein commenting on our recent
paper (1), in which we showed that the combination
of statin plus ezetimibe demonstrated greater
coronary plaque regression compared with statin
monotherapy. First of all, the PRECISE-IVUS (Plaque
Regression With Cholesterol Absorption Inhibitor
